Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing
Erin G. Sutcliffe(GenVec), Kathleen S. Hruska, Amy Stettner, Lisa R. Susswein, Maegan E. Roberts, Stacey Miller, Megan L. Marshall(St Mark's Hospital), Patricia D. Murphy(Newark Beth Israel Medical Center), Kevin J. Arvai, Rachel T. Klein, Sheila Solomon
Cited by 39
Related Papers
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.
|PubMed|1989|963
Evidence for 28 genetic disorders discovered by combining healthcare and research data
|Nature|2020|672
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing
|Genetics in Medicine|2015|292
Germline Genetic Testing After Cancer Diagnosis
|JAMA|2023|160